http://www.onemedplace.com/blog/wp-content/uploads/2009/05/pillsmoney.jpg
Investment website The Motley Fool has published a list of five stocks approaching greatness--and four of them are within the life sciences industry.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/06/scale1.jpg
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2...
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/06/weight.jpg
Yesterday, OneMedPlace reported on several companies that are developing anti-obesity drugs. Another name can be added to the list.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/06/obesity.jpg
The Our Resolution movement is focused around the discovery that gastric bypass surgery resolves diabetes in approximately 77 percent of morbidly obese patients.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/11/diabetes.jpg
Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/11/picotesla.jpg
Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most...
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/06/scale1.jpg
GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/07/echotherapeutics.jpg
The significant differences between Echo Therapeutics' Symphony system and the competition is the needle-free transdermal biosensor, clinical trials in the hospital setting and biosensor life.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/11/diabetes.jpg
The approval of Novo Nordisk's diabetes drug Victoza has led to an unintended benefit for a competitor.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2010/05/1059322_eye.jpg
A large-scale study funded by the National Institutes of Health found that both blood sugar control and a combination of cholesterol-lowering lipid drugs were effective in slowing the progression of...
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2010/04/computer-money.jpg
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
View Article
